{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:05:39Z","timestamp":1791993939476,"version":"4.4.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100022824","name":"Sanofi Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12325-024-03041-2","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T03:49:24Z","timestamp":1733370564000},"page":"597-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Current Therapies on Disease Progression in Fabry Disease: A Narrative Review for Better Patient Management in Clinical Practice"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8507-8939","authenticated-orcid":false,"given":"Renzo","family":"Mignani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Biagini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Cianci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonino","family":"Tuttolomondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Pieroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"3041_CR1","unstructured":"National Institute for Health and Care Excellence. Migalastat for treating Fabry disease: highly specialised technologies guidance HST4. 2017. http:\/\/www.nice.org.uk\/guidance\/hst4. Accessed 26 Oct 2022."},{"issue":"1","key":"3041_CR2","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","volume":"7","author":"M Niemann","year":"2014","unstructured":"Niemann M, Rolfs A, St\u00f6rk S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014;7(1):8\u201316.","journal-title":"Circ Cardiovasc Genet"},{"issue":"18","key":"3041_CR3","doi-asserted-by":"crossref","first-page":"10088","DOI":"10.3390\/ijms221810088","volume":"22","author":"A Tuttolomondo","year":"2021","unstructured":"Tuttolomondo A, Simonetta I, Riolo R, et al. Pathogenesis and molecular mechanisms of Anderson-Fabry disease and possible new molecular addressed therapeutic strategies. Int J Mol Sci. 2021;22(18):10088.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3041_CR4","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1038\/s41436-019-0451-z","volume":"21","author":"DP Germain","year":"2019","unstructured":"Germain DP, Nicholls K, Giugliani R, et al. Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension study. Genet Med. 2019;21(9):1987\u201397.","journal-title":"Genet Med"},{"issue":"1","key":"3041_CR5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, Korver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139.","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"3041_CR6","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jacc.2016.06.026","volume":"68","author":"AJ Marian","year":"2016","unstructured":"Marian AJ. Challenges in the diagnosis of Anderson-Fabry disease: a deceptively simple and yet complicated genetic disease. J Am Coll Cardiol. 2016;68(10):1051\u20133.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"3041_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-021-01019-3","volume":"13","author":"T Di Risi","year":"2021","unstructured":"Di Risi T, Vinciguerra R, Cuomo M, et al. DNA methylation impact on Fabry disease. Clin Epigenet. 2021;13(1):1\u20139.","journal-title":"Clin Epigenet"},{"issue":"4","key":"3041_CR8","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/cge.14102","volume":"101","author":"DP Germain","year":"2022","unstructured":"Germain DP, Levade T, Hachulla E, et al. Challenging the traditional approach for interpreting genetic variants: lessons from Fabry disease. Clin Genet. 2022;101(4):390\u2013402.","journal-title":"Clin Genet"},{"issue":"5","key":"3041_CR9","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201323.","journal-title":"Genet Med"},{"issue":"7","key":"3041_CR10","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jacc.2020.12.024","volume":"77","author":"M Pieroni","year":"2021","unstructured":"Pieroni M, Moon JC, Arbustini E, et al. Cardiac involvement in Fabry disease: JACC review topic of the week. J Am Coll Cardiol. 2021;77(7):922\u201336.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"3041_CR11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ymgme.2017.09.004","volume":"122","author":"P Rozenfeld","year":"2017","unstructured":"Rozenfeld P, Feriozzi S. Contribution of inflammatory pathways to Fabry disease pathogenesis. Mol Genet Metab. 2017;122(3):19\u201327.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3041_CR12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.3390\/jcm9041116","volume":"9","author":"M Ivanova","year":"2020","unstructured":"Ivanova M. Altered sphingolipids metabolism damaged mitochondrial functions: lessons learned from Gaucher and Fabry diseases. J Clin Med. 2020;9(4):1116.","journal-title":"J Clin Med"},{"key":"3041_CR13","unstructured":"Electronic Medicines Compendium. Summary of product characteristics: Galafold 123 mg 2016. https:\/\/www.medicines.org.uk\/emc\/product\/10934. Accessed 26 Oct 2022."},{"key":"3041_CR14","unstructured":"Electronic Medicines Compendium. Summary of product characteristics: Replagal 1mg\/ml concentrate for solution for infusion. 2022. https:\/\/www.medicines.org.uk\/emc\/product\/9186\/smpc#gref. Accessed 26 Oct 2022."},{"key":"3041_CR15","unstructured":"Electronic Medicines Compendium. Summary of product characteristics: Fabrazyme 35 mg powder for concentrate for solution for infusion. 2021. https:\/\/www.medicines.org.uk\/emc\/product\/8045\/smpc#gref. Accessed 26 Oct 2022."},{"key":"3041_CR16","unstructured":"European Medicines Agency. Elfabrio: EPAR summary for the public. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/elfabrio-epar-product-information_en.pdf. Accessed 2 Apr 2024."},{"key":"3041_CR17","unstructured":"European Medicines Agency. Fabrazyme: EPAR summary for the public. 2013. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fabrazyme. Accessed 26 Oct 2022."},{"key":"3041_CR18","unstructured":"European Medicines Agency. Replagal: EPAR summary for the public. 2015. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/replagal-epar-summary-public_en.pdf. Accessed 26 Oct 2022."},{"key":"3041_CR19","unstructured":"Takeda Canada Inc. Replagal product monograph. 2021. http:\/\/www.takeda.com\/en-ca\/replagalpm. Accessed 26 Oct 2022."},{"key":"3041_CR20","unstructured":"US Food and Drug Administration. Fabrazyme\u00ae (agalsidase beta) for injection, for intravenous use: prescribing information. 2003. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103979s5309lbl.pdf. Accessed 26 Oct 2022."},{"key":"3041_CR21","unstructured":"US Food and Drug Administration. Elfabrio (pegunigalsidase alfa-iwxj) injection, for intravenous use. 2023. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761161s000lbl.pdf. Accessed 2 Apr 2024."},{"key":"3041_CR22","unstructured":"US Food and Drug Administration. GalafoldTM (migalastat) capsules, for oral use: prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/208623lbl.pdf. Accessed 26 Oct 2022."},{"issue":"6","key":"3041_CR23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"key":"3041_CR24","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","volume":"19","author":"M Lenders","year":"2020","unstructured":"Lenders M, Stappers F, Brand E. In vitro and in vivo amenability to migalastat in Fabry disease. Mol Ther Methods Clin Dev. 2020;19:24\u201334.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"3041_CR25","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1523-1755.2002.00675.x","volume":"62","author":"BL Thurberg","year":"2002","unstructured":"Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int. 2002;62(6):1933\u201346.","journal-title":"Kidney Int"},{"issue":"4","key":"3041_CR26","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/cge.12386","volume":"86","author":"A Pisani","year":"2014","unstructured":"Pisani A, Visciano B, Imbriaco M, et al. The kidney in Fabry\u2019s disease. Clin Genet. 2014;86(4):301\u20139.","journal-title":"Clin Genet"},{"issue":"1","key":"3041_CR27","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000493469","volume":"141","author":"E Riccio","year":"2019","unstructured":"Riccio E, Sabbatini M, Bruzzese D, et al. Glomerular hyperfiltration: an early marker of nephropathy in Fabry disease. Nephron. 2019;141(1):10\u20137.","journal-title":"Nephron"},{"issue":"4","key":"3041_CR28","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1681\/ASN.2013060585","volume":"25","author":"F Weidemann","year":"2014","unstructured":"Weidemann F, Kr\u00e4mer J, Duning T, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol. 2014;25(4):837\u201349.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"3041_CR29","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/gfx009","volume":"33","author":"A Pisani","year":"2018","unstructured":"Pisani A, Petruzzelli Annicchiarico L, Pellegrino A, et al. Parapelvic cysts, a distinguishing feature of renal Fabry disease. Nephrol Dial Transplant. 2018;33(2):318\u201323.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"3041_CR30","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M, et al. Sustained, long-term renal stabilization after 54 months of agalsidase \u03b2 therapy in patients with Fabry disease. J Am Soc Nephrol. 2007;18(5):1547\u201357.","journal-title":"J Am Soc Nephrol"},{"key":"3041_CR31","doi-asserted-by":"crossref","unstructured":"Wraith JE, Tylki-Szymanska A, Guffon N et al. Safety and efficacy of enzyme replacement therapy with agalsidase beta: an international, open-label study in pediatric patients with Fabry disease. J Pediatr. 2008;152(4):563\u201370. e1.","DOI":"10.1016\/j.jpeds.2007.09.007"},{"issue":"3","key":"3041_CR32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ehf2.12647","volume":"7","author":"C Wanner","year":"2020","unstructured":"Wanner C, Feldt-Rasmussen U, Jovanovic A, et al. Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis. ESC Heart Fail. 2020;7(3):825\u201334.","journal-title":"ESC Heart Fail."},{"issue":"1","key":"3041_CR33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1086\/422366","volume":"75","author":"WR Wilcox","year":"2004","unstructured":"Wilcox WR, Banikazemi M, Guffon N, et al. Long-term safety and efficacy of enzyme replacement therapyfor fabry disease. Am J Hum Genet. 2004;75(1):65\u201374.","journal-title":"Am J Hum Genet"},{"issue":"13","key":"3041_CR34","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/hrt.2008.162800","volume":"95","author":"M Imbriaco","year":"2009","unstructured":"Imbriaco M, Pisani A, Spinelli L, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart. 2009;95(13):1103\u20137.","journal-title":"Heart"},{"issue":"5","key":"3041_CR35","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/jmedgenet-2014-102797","volume":"52","author":"DP Germain","year":"2015","unstructured":"Germain DP, Charrow J, Desnick RJ, et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet. 2015;52(5):353\u20138.","journal-title":"J Med Genet"},{"issue":"5","key":"3041_CR36","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1399-0004.2012.01947.x","volume":"83","author":"L Borgwardt","year":"2013","unstructured":"Borgwardt L, Feldt-Rasmussen U, Rasmussen AK, Ballegaard M, Meldgaard LA. Fabry disease in children: agalsidase-beta enzyme replacement therapy. Clin Genet. 2013;83(5):432\u20138.","journal-title":"Clin Genet"},{"issue":"2","key":"3041_CR37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med. 2007;146(2):77\u201386.","journal-title":"Ann Intern Med"},{"issue":"7","key":"3041_CR38","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1038\/sj.ki.5000208","volume":"69","author":"F Breunig","year":"2006","unstructured":"Breunig F, Weidemann F, Strotmann J, Knoll A, Wanner C. Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int. 2006;69(7):1216\u201321.","journal-title":"Kidney Int"},{"issue":"6","key":"3041_CR39","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","volume":"11","author":"C Whybra","year":"2009","unstructured":"Whybra C, Miebach E, Mengel E, et al. A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med. 2009;11(6):441\u20139.","journal-title":"Genet Med"},{"issue":"9","key":"3041_CR40","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3109\/08860220903150296","volume":"31","author":"S Thofehrn","year":"2009","unstructured":"Thofehrn S, Netto C, Cecchin C, et al. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience. Ren Fail. 2009;31(9):773\u20138.","journal-title":"Ren Fail"},{"key":"3041_CR41","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13023-015-0338-2","volume":"10","author":"C Kampmann","year":"2015","unstructured":"Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years\u2019 treatment. Orphanet J Rare Dis. 2015;10:125.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3041_CR42","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U, et al. Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Investig. 2004;34(12):838\u201344.","journal-title":"Eur J Clin Investig"},{"key":"3041_CR43","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","volume":"13","author":"U Ramaswami","year":"2019","unstructured":"Ramaswami U, Beck M, Hughes D, et al. Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry Outcome Survey (FOS) analysis. Drug Des Dev Ther. 2019;13:3705.","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"3041_CR44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/ndt\/gfi152","volume":"21","author":"R Schiffmann","year":"2006","unstructured":"Schiffmann R, Ries M, Timmons M, Flaherty JT, Brady RO. Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol Dial Transplant. 2006;21(2):345\u201354.","journal-title":"Nephrol Dial Transplant"},{"key":"3041_CR45","doi-asserted-by":"crossref","unstructured":"Hughes DA, Romero M-\u00c1B, Hollak CE, Giugliani R, Deegan PB. Response of women with Fabry disease to enzyme replacement therapy: comparison with men, using data from FOS\u2014the Fabry Outcome Survey. Mol Genet Metab. 2011;103(3):207\u201314.","DOI":"10.1016\/j.ymgme.2011.03.022"},{"issue":"5","key":"3041_CR46","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1681\/ASN.2006111263","volume":"18","author":"R Schiffmann","year":"2007","unstructured":"Schiffmann R, Askari H, Timmons M, et al. Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing. J Am Soc Nephrol. 2007;18(5):1576\u201383.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"3041_CR47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173358","volume":"12","author":"R El Dib","year":"2017","unstructured":"El Dib R, Gomaa H, Ortiz A, Politei J, Kapoor A, Barreto F. Enzyme replacement therapy for Anderson-Fabry disease: a complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS ONE. 2017;12(3): e0173358.","journal-title":"PLoS ONE"},{"issue":"5","key":"3041_CR48","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/jmedgenet-2017-104863","volume":"55","author":"M Arends","year":"2018","unstructured":"Arends M, Biegstraaten M, Wanner C, et al. Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study. J Med Genet. 2018;55(5):351\u20138.","journal-title":"J Med Genet"},{"issue":"7","key":"3041_CR49","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1371\/journal.pone.0000598","volume":"2","author":"AC Vedder","year":"2007","unstructured":"Vedder AC, Linthorst GE, Houge G, et al. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg\/kg. PLoS ONE. 2007;2(7):e598.","journal-title":"PLoS ONE"},{"key":"3041_CR50","first-page":"41","volume":"9","author":"A Pisani","year":"2013","unstructured":"Pisani A, Spinelli L, Visciano B, et al. Effects of switching from agalsidase beta to agalsidase alfa in 10 patients with Anderson-Fabry disease. JIMD Rep. 2013;9:41\u20138.","journal-title":"JIMD Rep"},{"issue":"9","key":"3041_CR51","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/gim.2012.39","volume":"14","author":"K Tsuboi","year":"2012","unstructured":"Tsuboi K, Yamamoto H. Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal). Genet Med. 2012;14(9):779\u201386.","journal-title":"Genet Med"},{"issue":"3","key":"3041_CR52","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1681\/ASN.2015030337","volume":"27","author":"M Lenders","year":"2016","unstructured":"Lenders M, Canaan-K\u00fchl S, Kr\u00e4mer J, et al. Patients with Fabry disease after enzyme replacement therapy dose reduction and switch-2-year follow-up. J Am Soc Nephrol. 2016;27(3):952\u201362.","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"3041_CR53","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ndt\/gfx319","volume":"33","author":"J Kr\u00e4mer","year":"2018","unstructured":"Kr\u00e4mer J, Lenders M, Canaan-K\u00fchl S, et al. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages. Nephrol Dial Transplant. 2018;33(8):1362\u201372.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3041_CR54","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/gim.2016.117","volume":"19","author":"A Pisani","year":"2017","unstructured":"Pisani A, Bruzzese D, Sabbatini M, Spinelli L, Imbriaco M, Riccio E. Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature. Genet Med. 2017;19(3):275\u201382.","journal-title":"Genet Med"},{"issue":"3","key":"3041_CR55","first-page":"173","volume":"77","author":"D Ripeau","year":"2017","unstructured":"Ripeau D, Amartino H, Cedrolla M, et al. Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America. Medicina (B Aires). 2017;77(3):173\u20139.","journal-title":"Medicina (B Aires)"},{"issue":"3","key":"3041_CR56","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/cge.14266","volume":"103","author":"E Riccio","year":"2023","unstructured":"Riccio E, Pisani A. New insights in efficacy of different enzyme replacement therapy dosages in Fabry disease: switch studies data following agalsidase beta shortage. Clin Genet. 2023;103(3):371\u20136.","journal-title":"Clin Genet"},{"issue":"1\u20132","key":"3041_CR57","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"3041_CR58","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10157-019-01810-w","volume":"24","author":"I Narita","year":"2020","unstructured":"Narita I, Ohashi T, Sakai N, et al. Efficacy and safety of migalastat in a Japanese population: a subgroup analysis of the ATTRACT study. Clin Exp Nephrol. 2020;24(2):157\u201366.","journal-title":"Clin Exp Nephrol"},{"issue":"1\u20132","key":"3041_CR59","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ymgme.2020.07.007","volume":"131","author":"U Feldt-Rasmussen","year":"2020","unstructured":"Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020;131(1\u20132):219\u201328.","journal-title":"Mol Genet Metab"},{"issue":"4","key":"3041_CR60","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","volume":"54","author":"DA Hughes","year":"2017","unstructured":"Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study. J Med Genet. 2017;54(4):288\u201396.","journal-title":"J Med Genet"},{"issue":"9","key":"3041_CR61","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1136\/jmg-2022-108768","volume":"60","author":"A Camporeale","year":"2023","unstructured":"Camporeale A, Bandera F, Pieroni M, et al. Effect of migalastat on cArdiac involvement in FabRry disease: MAIORA study. J Med Genet. 2023;60(9):850\u20138.","journal-title":"J Med Genet"},{"issue":"5","key":"3041_CR62","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cpt.1321","volume":"105","author":"J M\u00fcntze","year":"2019","unstructured":"M\u00fcntze J, Gensler D, Maniuc O, et al. Oral chaperone therapy migalastat for treating Fabry disease: enzymatic response and serum biomarker changes after 1 year. Clin Pharmacol Ther. 2019;105(5):1224\u201333.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3041_CR63","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.1832","volume":"108","author":"M Lenders","year":"2020","unstructured":"Lenders M, Nordbeck P, Kurschat C, et al. Treatment of Fabry\u2019s disease with migalastat: outcome from a prospective observational multicenter study (FAMOUS). Clin Pharmacol Ther. 2020;108(2):326\u201337.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"3041_CR64","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1093\/ehjcvp\/pvab025","volume":"8","author":"M Lenders","year":"2022","unstructured":"Lenders M, Nordbeck P, Kurschat C, et al. Treatment of Fabry disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS). Eur Heart J Cardiovasc Pharmacother. 2022;8(3):272\u201381.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"3041_CR65","volume":"28","author":"DG Bichet","year":"2021","unstructured":"Bichet DG, Torra R, Wallace E, et al. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease. Mol Genet Metab Rep. 2021;28: 100786.","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"3041_CR66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1136\/jmg-2022-108669","volume":"60","author":"DA Hughes","year":"2022","unstructured":"Hughes DA, Bichet DG, Giugliani R, et al. Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes. J Med Genet. 2022;60(7):722\u201331.","journal-title":"J Med Genet"},{"key":"3041_CR67","doi-asserted-by":"crossref","unstructured":"Pisani A, Wilson KM, Batista JL et al. Clinical outcomes in patients switching from agalsidase beta to migalastat: a Fabry Registry analysis. J Inherit Metab Dis. 2024.","DOI":"10.1016\/j.ymgme.2023.107999"},{"issue":"20","key":"3041_CR68","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1212\/WNL.0000000000002673","volume":"86","author":"NS Rost","year":"2016","unstructured":"Rost NS, Cloonan L, Kanakis AS, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology. 2016;86(20):1880\u20136.","journal-title":"Neurology"},{"issue":"12","key":"3041_CR69","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143940","volume":"10","author":"K Korsholm","year":"2015","unstructured":"Korsholm K, Feldt-Rasmussen U, Granqvist H, et al. Positron emission tomography and magnetic resonance imaging of the brain in fabry disease: a nationwide, long-time, prospective follow-up. PLoS ONE. 2015;10(12): e0143940.","journal-title":"PLoS ONE"},{"key":"3041_CR70","volume":"29","author":"D Tapia","year":"2021","unstructured":"Tapia D, Floriolli D, Han E, et al. Prevalence of cerebral small vessel disease in a Fabry disease cohort. Mol Genet Metab Rep. 2021;29: 100815.","journal-title":"Mol Genet Metab Rep"},{"issue":"5","key":"3041_CR71","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2016090964","volume":"28","author":"M Arends","year":"2017","unstructured":"Arends M, Wanner C, Hughes D, et al. Characterization of classical and nonclassical Fabry disease: a multicenter study. J Am Soc Nephrol. 2017;28(5):1631\u201341.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"3041_CR72","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1093\/brain\/awaa282","volume":"143","author":"L Ulivi","year":"2020","unstructured":"Ulivi L, Kanber B, Prados F, et al. White matter integrity correlates with cognition and disease severity in Fabry disease. Brain. 2020;143(11):3331\u201342.","journal-title":"Brain"},{"issue":"11","key":"3041_CR73","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1136\/jnnp.2008.143693","volume":"79","author":"S Buechner","year":"2008","unstructured":"Buechner S, Moretti M, Burlina AP, et al. Central nervous system involvement in Anderson-Fabry disease: a clinical and MRI retrospective study. J Neurol Neurosurg Psychiatry Res. 2008;79(11):1249\u201354.","journal-title":"J Neurol Neurosurg Psychiatry Res"},{"issue":"6","key":"3041_CR74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000369293","volume":"38","author":"A Fellgiebel","year":"2014","unstructured":"Fellgiebel A, Gartenschl\u00e4ger M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis. 2014;38(6):448\u201356.","journal-title":"Cerebrovasc Dis"},{"key":"3041_CR75","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jocn.2019.03.064","volume":"65","author":"S Sheng","year":"2019","unstructured":"Sheng S, Wu L, Nalleballe K, et al. Fabry\u2019s disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. J Clin Neurosci. 2019;65:83\u20136.","journal-title":"J Clin Neurosci"},{"issue":"2","key":"3041_CR76","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1023\/B:BOLI.0000028794.04349.91","volume":"27","author":"L Jardim","year":"2004","unstructured":"Jardim L, Vedolin L, Schwartz IVD, et al. CNS involvement in Fabry disease: clinical and imaging studies before and after 12 months of enzyme replacement therapy. J Inherit Metab Dis. 2004;27(2):229\u201340.","journal-title":"J Inherit Metab Dis"},{"key":"3041_CR77","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/j.1651-2227.2003.tb00217.x","volume":"92","author":"D Hajioff","year":"2003","unstructured":"Hajioff D, Goodwin S, Quiney R, Zuckerman J, MacDermot K, Mehta A. Hearing improvement in patients with Fabry disease treated with agalsidase alfa. Acta Paediatr. 2003;92:28\u201330.","journal-title":"Acta Paediatr"},{"issue":"8","key":"3041_CR78","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","volume":"46","author":"A Mehta","year":"2009","unstructured":"Mehta A, Clarke JT, Giugliani R, et al. Natural course of Fabry disease: changing pattern of causes of death in FOS\u2013Fabry Outcome Survey. J Med Genet. 2009;46(8):548\u201352.","journal-title":"J Med Genet"},{"key":"3041_CR79","first-page":"53","volume":"11","author":"S Havranek","year":"2013","unstructured":"Havranek S, Linhart A, Urbanova Z, Ramaswami U. Early cardiac changes in children with Anderson-Fabry disease. JIMD Rep. 2013;11:53\u201364.","journal-title":"JIMD Rep"},{"key":"3041_CR80","doi-asserted-by":"crossref","unstructured":"Nordin S, Kozor R, Medina-Menacho K, et al. Proposed stages of myocardial phenotype development in Fabry disease. JACC Cardiovasc Imaging. 2019;12(8 Part 2):1673\u201383.","DOI":"10.1016\/j.jcmg.2018.03.020"},{"issue":"11","key":"3041_CR81","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","volume":"108","author":"F Weidemann","year":"2003","unstructured":"Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108(11):1299\u2013301.","journal-title":"Circulation"},{"issue":"7","key":"3041_CR82","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1097\/HJH.0b013e328336a077","volume":"28","author":"MJ Hilz","year":"2010","unstructured":"Hilz MJ, Marthol H, Schwab S, Kolodny EH, Brys M, Stemper B. Enzyme replacement therapy improves cardiovascular responses to orthostatic challenge in Fabry patients. J Hypertens. 2010;28(7):1438\u201348.","journal-title":"J Hypertens"},{"issue":"1","key":"3041_CR83","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s10545-006-0221-3","volume":"29","author":"R Kalliokoski","year":"2006","unstructured":"Kalliokoski R, Kantola I, Kalliokoski K, et al. The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. J Inherit Metab Dis. 2006;29(1):112\u20138.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"3041_CR84","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ijcard.2012.12.002","volume":"168","author":"V Ruddox","year":"2013","unstructured":"Ruddox V, Mathisen M, B\u00e6kkevar M, Aune E, Edvardsen T, Otterstad JE. Is 3D echocardiography superior to 2D echocardiography in general practice? A systematic review of studies published between 2007 and 2012. Int J Cardiol. 2013;168(2):1306\u201315.","journal-title":"Int J Cardiol"},{"issue":"2","key":"3041_CR85","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/hrt.2006.104026","volume":"94","author":"DA Hughes","year":"2008","unstructured":"Hughes DA, Elliott PM, Shah J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94(2):153\u20138.","journal-title":"Heart"},{"issue":"8","key":"3041_CR86","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jcmg.2020.03.004","volume":"13","author":"R Vijapurapu","year":"2020","unstructured":"Vijapurapu R, Baig S, Nordin S, et al. Longitudinal assessment of cardiac involvement in Fabry disease using cardiovascular magnetic resonance imaging. JACC Cardiovasc Imaging. 2020;13(8):1850\u20132.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"3041_CR87","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41431-020-0677-x","volume":"28","author":"E Riccio","year":"2020","unstructured":"Riccio E, Zanfardino M, Ferreri L, et al. Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data. Eur J Hum Genet. 2020;28(12):1662\u20138.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"3041_CR88","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1007\/s12325-019-01061-x","volume":"36","author":"O Morand","year":"2019","unstructured":"Morand O, Johnson J, Walter J, et al. Symptoms and quality of life in patients with Fabry disease: results from an international patient survey. Adv Ther. 2019;36(10):2866\u201380.","journal-title":"Adv Ther"},{"issue":"12","key":"3041_CR89","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S, Investigators FOSE. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447\u201353.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"3041_CR90","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","volume":"30","author":"C Eng","year":"2007","unstructured":"Eng C, Fletcher J, Wilcox W, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007;30(2):184\u201392.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"3041_CR91","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","volume":"85","author":"M Banikazemi","year":"2005","unstructured":"Banikazemi M, Ullman T, Desnick RJ. Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy. Mol Genet Metab. 2005;85(4):255\u20139.","journal-title":"Mol Genet Metab"},{"key":"3041_CR92","volume":"25","author":"RJ Hopkin","year":"2020","unstructured":"Hopkin RJ, Feldt-Rasmussen U, Germain DP, et al. Improvement of gastrointestinal symptoms in a significant proportion of male patients with classic Fabry disease treated with agalsidase beta: a Fabry Registry analysis stratified by phenotype. Mol Genet Metab Rep. 2020;25: 100670.","journal-title":"Mol Genet Metab Rep"},{"key":"3041_CR93","first-page":"45","volume":"38","author":"WR Wilcox","year":"2018","unstructured":"Wilcox WR, Feldt-Rasmussen U, Martins AM, et al. Improvement of Fabry disease-related gastrointestinal symptoms in a significant proportion of female patients treated with agalsidase beta: data from the Fabry Registry. JIMD Rep. 2018;38:45\u201351.","journal-title":"JIMD Rep"},{"issue":"11","key":"3041_CR94","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1097\/GIM.0b013e3181f13a4a","volume":"12","author":"T Watt","year":"2010","unstructured":"Watt T, Burlina AP, Cazzorla C, et al. Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry Registry. Genet Med. 2010;12(11):703\u201312.","journal-title":"Genet Med"},{"issue":"1","key":"3041_CR95","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-018-0813-7","volume":"13","author":"R Schiffmann","year":"2018","unstructured":"Schiffmann R, Bichet DG, Jovanovic A, et al. Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial. Orphanet J Rare Dis. 2018;13(1):1\u20137.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3041_CR96","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dost\u00e1lov\u00e1 G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study. Orphanet J Rare Dis. 2023;18(1):332.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"3041_CR97","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study. J Med Genet. 2024;61(6):520\u201330.","journal-title":"J Med Genet"},{"issue":"3","key":"3041_CR98","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/j.gim.2022.01.185","volume":"24","author":"J Bernat","year":"2022","unstructured":"Bernat J, Holida M, Longo N, et al. eP149: Safety and efficacy of pegunigalsidase alfa, every 4 weeks, in Fabry disease: results from the phase 3, open-label, BRIGHT study. Genet Med. 2022;24(3):S91\u20132.","journal-title":"Genet Med"},{"key":"3041_CR99","unstructured":"European Medicines Agency Committee for Medicinal Products for Human Use (CHMP). Assessment report: Elfabrio, Procedure No. EMEA\/H\/C\/005618\/0000. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elfabrio. Accessed 20 Sept 2024."},{"key":"3041_CR100","unstructured":"European Medicines Agency. Elfabrio: EPAR-product information. 2023. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elfabrio. Accessed 20 Sept 2024."},{"issue":"2","key":"3041_CR101","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ymgme.2007.09.013","volume":"93","author":"WR Wilcox","year":"2008","unstructured":"Wilcox WR, Oliveira JP, Hopkin RJ, et al. Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab. 2008;93(2):112\u201328.","journal-title":"Mol Genet Metab"},{"key":"3041_CR102","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s13023-015-0253-6","volume":"10","author":"M Biegstraaten","year":"2015","unstructured":"Biegstraaten M, Arngr\u00edmsson R, Barbey F, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis. 2015;10:36.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"3041_CR103","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","volume":"22","author":"A Linhart","year":"2020","unstructured":"Linhart A, Germain DP, Olivotto I, et al. An expert consensus document on the management of cardiovascular manifestations of Fabry disease. Eur J Heart Fail. 2020;22(7):1076\u201396.","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"3041_CR104","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"issue":"23","key":"3041_CR105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1136\/heartjnl-2020-317922","volume":"107","author":"M El Sayed","year":"2021","unstructured":"El Sayed M, Hirsch A, Boekholdt M, et al. Influence of sex and phenotype on cardiac outcomes in patients with Fabry disease. Heart. 2021;107(23):1889\u201397.","journal-title":"Heart"},{"issue":"1","key":"3041_CR106","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfad164","volume":"39","author":"A Pisani","year":"2023","unstructured":"Pisani A, Pieruzzi F, Cirami CL, Riccio E, Mignani R. Interpretation of GFR slope in untreated and treated adult Fabry patients. Nephrol Dial Transplant. 2023;39(1):18\u201325.","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"3041_CR107","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1681\/ASN.2018070740","volume":"29","author":"M Lenders","year":"2018","unstructured":"Lenders M, Neusser LP, Rudnicki M, et al. Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease. J Am Soc Nephrol. 2018;29(12):2879\u201389.","journal-title":"J Am Soc Nephrol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03041-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03041-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T05:52:51Z","timestamp":1738389171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03041-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["3041"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03041-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"11 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Renzo Mignani has received speaker and advisory board honoraria and travel support from Amicus Therapeutics, Chiesi, Takeda, and Sanofi. Maurizio Pieroni has received speaker and advisory board honoraria and travel support from Amicus Therapeutics, Chiesi, Takeda, and Sanofi. Elena Biagini has received speaker and advisory board honoraria and travel support from Amicus Therapeutics, Chiesi, Takeda, Genzyme, and BMS. Vittoria Cianci, Federico Pieruzzi, Antonio Pisani, and Antonino Tuttolomondo have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}